Literature DB >> 236513

Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man.

W A Pettinger, H C Mitchell.   

Abstract

Saralasin, an angiotensin antagonist, was used to study the role of renin-angiotensin in the vasodilator-beta-blocker drug interaction in hypertensive subjects. Plasma renin activity was elevated by withdrawal of propranolol in seven patients using minoxidil and propranolol. After propranolol withdrawal, saralasin caused hypotension (100/60 mm Hg or less) in five. Propranolol lowered blood pressure and plasma renin activity and diminished the hypotensive response to saralasin. Saralasin induced renin release in all patients, an effect blocked by propranolol. We conclude that angiotensin can be the major determinant of blood pressure in vasodilator-drug treated patients, that propranolol lowering of blood pressure in this vasodilator-beta-blocker drug interaction is related to suppression of renin release, and that the angiotensin feed-back-suppression mechanism for inhibiting renin release in functionally located proximal to beta-adrenergic receptors mediating renin release.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 236513     DOI: 10.1056/NEJM197506052922304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

1.  [Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl)].

Authors:  A Röckel; H Wernze; B Sabel; A Heidland
Journal:  Klin Wochenschr       Date:  1977-07-01

Review 2.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

3.  Antihypertensive and renal effects of orally administered verapamil.

Authors:  G Leonetti; C Sala; C Bianchini; L Terzoli; A Zanchetti
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

4.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

Authors:  S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

5.  Mechanism of the interaction of propranolol and a potent vasodilator antihypertensive agent - minoxidil.

Authors:  K O'Malley; M Velasco; J Wells; J McNay
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

6.  Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension.

Authors:  M G Bianchetti; P Weidmann; K Boehringer; L Link; H Schiffl; C Beretta-Piccoli; J P Colombo
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Effect of antihypertensive drugs on the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1976       Impact factor: 9.546

8.  Catecholamines, renin, aldosterone, and blood volume during chronic minoxidil therapy.

Authors:  A Meier; P Weidmann; W H Ziegler
Journal:  Klin Wochenschr       Date:  1981-11-16

9.  Immediate plasma renin response to propranolol: differentiation between essential and renal hypertension.

Authors:  F Skrabal; W Czaykowska; P Dittrich; H Braunsteiner
Journal:  Br Med J       Date:  1976-07-17

10.  Clinical evaluation of a new antihypertensive vasodilating agent PR--G 138 Cl.

Authors:  J Vos; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.